Opyt primeneniya oktreotida v prolongirovannoy forme vypuska pri lechenii kastrat-rezistentnogo raka predstatel'noy zhelezy
- Autores: Mishugin S.V1, Mordovin A.A1, Gritskevich A.A1, Rusakov I.G1
-
Afiliações:
- Edição: Nº 8 (2015)
- Páginas: 40-43
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287932
- ID: 287932
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The study was aimed to the evaluation of the efficacy of octreotide long-acting release form, depending on the applied dose (20 mg or 30 mg), by studying the dynamics of the prostate specific antigen levels. The study has shown high effectiveness of octreotide at a dose of 30 mg - a positive response to treatment (reduction or stabilization of prostate specific antigen levels, symptomatic effect) was observed in almost 80% of patients.
Palavras-chave
Texto integral
Bibliografia
- Boyle H., Ferlay J. Cancer incidence and mortality in Europe 2004. Ann. Oncol. 2005;16(3): 481-88.
- Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 году. М., 2014.
- Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году. М., 2013.
- Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Российской Федерации. Экспериментальная и клиническая урология. 2011:2-3.
- Pagliarulo V., Bracarda S., Eisenberger M.A., Motter N, Schroder F.H. Contemporary role of androgen deprivation therapy for prostate cancer. Eur. Urol. 2012;61:11-25.
- Abrahamson Per-Anders. Revolutions in the management of hormone-refractory prostate cancer. European Urology Supplements. 2003;2:1-2.
- Crawford D.E., Rosenblum M., Ziada A.M., Lange P.H. Overview: hormone-refractory prostate cancer. Urology. 1999;54(6A Suppl):1-7.
- Гарин А.М. Доцетаксел (Таксотер) в практике лечения злокачественных опухолей. М., 2003. C. 88-94.
- Русаков И.Г., Грицкевич А.А. Возможности аналогов соматостатина в лечении кастрационно-резистентного рака предстательной железы. Онкология. Журнал им. П.А. Герцена. 2012;1:73-6.
- Pollak M.N., Schally A.V. Mechanism of antineoplastic action of somatostatin analogs. Proc. Soc. Exp. Biol. Med. 1998;217:143-52.
- Vainas I.G. Octreotide in the manage ment of hormonerefractory prostate cancer. Chemotherapy. 2001;47:109-26.
- Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Akiyama M., Hideshima T., Chauhan D., Joseph M., Libermann T.A., Garca-Echeverria C., Pearson M.A., Hofmann F., Anderson K.C., Kung A.L. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5(3):221-30.
- Saltz L., Trochanowski B., Buckley M., Heffernan B., Niedzwiecki D., Tao Y., Kelsen D. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993; 72:244-48.
Arquivos suplementares
